Status:
COMPLETED
Blood and Tissue Study of Patients in NIH Protocol 08-C-0800
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Sarcomas
Eligibility:
All Genders
2-99 years
Brief Summary
Background: * This study is a companion biology study to NIH protocol 08-C-0080, A Phase II Trial of R1507, a Recombinant Human Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment...
Detailed Description
Background: * R1507 is a recombinant, fully human monoclonal IgG1 antibody that binds specifically to the human IGF-1R, resulting in direct inhibition of ligand binding and loss of receptor protein o...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- All patients enrolled on the Phase II study SARC011/N021157 will be eligible for enrollment.
- Signed informed consent for this study according to institutional guidelines is required.
- EXCLUSION CRITERIA:
- None.
Exclusion
Key Trial Info
Start Date :
December 9 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2017
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00923325
Start Date
December 9 2008
End Date
May 18 2017
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892